Table 2. Changes in secondary efficacy variables from baseline to end of treatment (full analysis set).
| Variable | Placebo | Ipragliflozin | Adjusted mean difference (95% CI) | P valuea | ||
|---|---|---|---|---|---|---|
| Mean±SD | Number | Mean±SD | Number | |||
| HOMA-IR | 0.41±1.78 | 35 | –0.34±1.79 | 38 | –0.75 (–1.59 to 0.09) | 0.079 |
| HOMA-β | –1.37±77.07 | 35 | 6.24±36.68 | 38 | 2.88 (–20.58 to 26.34) | 0.807 |
| Body weight, kg | –1.13±1.90 | 39 | –2.66±2.20 | 43 | –1.53 (–2.44 to –0.61) | 0.001 |
| Waist circumference, cm | –0.90±2.68 | 36 | –1.23±2.43 | 39 | –0.26 (–1.45 to 0.92) | 0.661 |
| FSI, µIU/mL | 1.14±4.41 | 37 | 0.07±4.63 | 39 | –0.90 (–2.93 to 1.12) | 0.376 |
SD, standard deviation; CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell function; FSI, fasting serum insulin.
aAnalysis of covariance model including baseline value as a covariate.